RxDoctor Payments Data

Sarah Cherry

Gerontology · Indianapolis, INNPI 1750844890

Payments from drug & device makers

$1,047in general payments, 2019–2025

Across 39 payments — averaging $26.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$483
  • Sumitomo Pharma America, Inc.$197
  • AstraZeneca$189
  • Avanir Pharmaceuticals, Inc.$64
  • Otsuka America Pharmaceutical, Inc.$47
  • Neurocrine Biosciences, Inc.$44
  • plus $23 from 1 others

What the payments were for

  • Food & beverage$1,047100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,047 in reported general payments places this provider in the 70th percentile of 230 gerontology providers in Indiana.

See all gerontology providers in Indiana

Medicare billing

Part B allowed, 2024
$134,890
Medicare patients
245
Services billed
1,650

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban592$170,742
TradjentaLinagliptin245$64,584
TrulicityDulaglutide89$57,101
JardianceEmpagliflozin157$51,043
XifaxanRifaximin22$35,515
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr54$26,946
AptiomEslicarbazepine Acetate27$19,992
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$19,370
XareltoRivaroxaban60$18,316
AbrysvoRsv Vacc, Pref A And Pref B/Pf43$13,510
Memantine Hcl488$13,107
Divalproex Sodium330$11,749
Rivastigmine63$10,237
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen580$9,882
Potassium Chloride427$9,595

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sunovion Pharmaceuticals Inc.Aptiom$483$19,99227 claims
Avanir Pharmaceuticals, Inc.Nuedexta$64$8,74412 claims
Sumitomo Pharma America, Inc.Gemtesa$197$6,54221 claims
AstraZenecaFarxiga$189$3,82512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 230 gerontology providers in Indiana.

Other gerontology in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →